Lake Street Capital Forecasts Strong Price Appreciation for Semler Scientific (NASDAQ:SMLR) Stock

Semler Scientific (NASDAQ:SMLR) had its price objective lifted by investment analysts at Lake Street Capital from $40.00 to $71.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Lake Street Capital’s price objective indicates a potential upside of 28.02% from the stock’s current price.

Semler Scientific Trading Down 9.3 %

Shares of NASDAQ:SMLR opened at $55.46 on Friday. The company has a 50 day moving average of $60.44 and a 200-day moving average of $40.35. The firm has a market cap of $514.11 million, a P/E ratio of 27.05 and a beta of 1.18. Semler Scientific has a twelve month low of $20.88 and a twelve month high of $81.56.

Semler Scientific (NASDAQ:SMLR) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.35. Semler Scientific had a return on equity of 20.31% and a net margin of 27.00%. The company had revenue of $13.51 million for the quarter.

Hedge Funds Weigh In On Semler Scientific

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Newbridge Financial Services Group Inc. purchased a new stake in Semler Scientific in the 2nd quarter worth about $34,000. Quest Partners LLC lifted its position in Semler Scientific by 48.0% in the 3rd quarter. Quest Partners LLC now owns 2,520 shares of the company’s stock worth $59,000 after buying an additional 817 shares in the last quarter. US Bancorp DE boosted its stake in shares of Semler Scientific by 60.8% during the 3rd quarter. US Bancorp DE now owns 3,064 shares of the company’s stock valued at $72,000 after buying an additional 1,158 shares during the period. Sanctuary Advisors LLC acquired a new position in shares of Semler Scientific in the third quarter worth $104,000. Finally, Rhumbline Advisers raised its holdings in shares of Semler Scientific by 27.1% during the second quarter. Rhumbline Advisers now owns 6,197 shares of the company’s stock worth $213,000 after acquiring an additional 1,320 shares in the last quarter. Institutional investors and hedge funds own 49.37% of the company’s stock.

Semler Scientific Company Profile

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition.